6P91 image
Entry Detail
PDB ID:
6P91
Title:
Structure of Lassa virus glycoprotein bound to Fab 18.5C
Biological Source:
PDB Version:
Deposition Date:
2019-06-09
Release Date:
2019-08-21
Method Details:
Experimental Method:
Resolution:
4.00 Å
R-Value Free:
0.25
R-Value Work:
0.20
R-Value Observed:
0.20
Space Group:
I 21 3
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Pre-glycoprotein polyprotein GP complex
Mutations:R207C
Chain IDs:A
Chain Length:200
Number of Molecules:1
Biological Source:Lassa mammarenavirus
Polymer Type:polypeptide(L)
Description:Fab 18.5C Antibody heavy chain
Chain IDs:B (auth: H)
Chain Length:228
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Fab 18.5C Antibody light chain
Chain IDs:C (auth: L)
Chain Length:217
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Pre-glycoprotein polyprotein GP complex,Lassa virus glycoprotein, GP2 subunit
Mutations:E329P
Chain IDs:D (auth: a)
Chain Length:200
Number of Molecules:1
Biological Source:Lassa mammarenavirus
Ligand Molecules
Primary Citation
Convergent Structures Illuminate Features for Germline Antibody Binding and Pan-Lassa Virus Neutralization.
Cell 178 1004 1015.e14 (2019)
PMID: 31398326 DOI: 10.1016/j.cell.2019.07.020

Abstact

Lassa virus (LASV) causes hemorrhagic fever and is endemic in West Africa. Protective antibody responses primarily target the LASV surface glycoprotein (GPC), and GPC-B competition group antibodies often show potent neutralizing activity in humans. However, which features confer potent and broadly neutralizing antibody responses is unclear. Here, we compared three crystal structures of LASV GPC complexed with GPC-B antibodies of varying neutralization potency. Each GPC-B antibody recognized an overlapping epitope involved in binding of two adjacent GPC monomers and preserved the prefusion trimeric conformation. Differences among GPC-antibody interactions highlighted specific residues that enhance neutralization. Using structure-guided amino acid substitutions, we increased the neutralization potency and breadth of these antibodies to include all major LASV lineages. The ability to define antibody residues that allow potent and broad neutralizing activity, together with findings from analyses of inferred germline precursors, is critical to develop potent therapeutics and for vaccine design and assessment.

Legend

Protein

Chemical

Disease

Primary Citation of related structures